Your browser doesn't support javascript.
loading
Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
Crespo, Guillermo; Jiménez-Fonseca, Paula; Custodio, Ana; López, Carlos; Carmona-Bayonas, Alberto; Alonso, Vicente; Navarro, Miguel; Aller, Javier; Sevilla, Isabel; Grande, Enrique; Gajate, Pablo; Alonso-Gordoa, Teresa; Matos, Ignacio; Capdevila, Jaume; Nieto, Beatriz; Barriuso, Jorge.
Affiliation
  • Crespo G; Department of Medical Oncology, Hospital Universitario de Burgos, Burgos, Spain.
  • Jiménez-Fonseca P; Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain.
  • Custodio A; Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain.
  • López C; Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Carmona-Bayonas A; Department of Medical Oncology, Hospital Universitario Morales Meseguer, Murcia, Spain.
  • Alonso V; Department of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Navarro M; Department of Medical Oncology, Hospital Clínico Universitario de Salamanca, Salamanca, Spain.
  • Aller J; Endocrinology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Sevilla I; Department of Medical Oncology, Hospital Clínico Virgen de la Victoria y Regional de Málaga, Málaga, Spain.
  • Grande E; Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Gajate P; Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Alonso-Gordoa T; Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Matos I; Department of Medical Oncology, Hospital Universitari Vall d'Hebron, Universitat Autónoma de Barcelona, Barcelona, Spain.
  • Capdevila J; Department of Medical Oncology, Hospital Universitari Vall d'Hebron, Universitat Autónoma de Barcelona, Barcelona, Spain.
  • Nieto B; Department of Medical Oncology, Hospital Universitario de León, León, Spain.
  • Barriuso J; Department of Medical Oncology, University of Manchester, Manchester, UK.
Future Oncol ; 13(7): 615-624, 2017 Mar.
Article de En | MEDLINE | ID: mdl-27802780
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protocoles de polychimiothérapie antinéoplasique / Tumeurs neuroendocrines Type d'étude: Clinical_trials / Prognostic_studies / Risk_factors_studies Limites: Aged / Female / Humans / Male / Middle aged Pays/Région comme sujet: Europa Langue: En Journal: Future Oncol Année: 2017 Type de document: Article Pays d'affiliation: Espagne
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Protocoles de polychimiothérapie antinéoplasique / Tumeurs neuroendocrines Type d'étude: Clinical_trials / Prognostic_studies / Risk_factors_studies Limites: Aged / Female / Humans / Male / Middle aged Pays/Région comme sujet: Europa Langue: En Journal: Future Oncol Année: 2017 Type de document: Article Pays d'affiliation: Espagne